Clinical Trial

A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients

Study acronym: MODERN
Recruiting
View on ClinicalTrials.gov →
Summary
A multi-centre, multi-country, observational, non-interventional, retrospective and prospective (hybrid) study among Fabry disease participants treated with pegunigalsidase alfa (Elfabrio®) in routine clinical care.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-10-25; most recent amendment 2025-11-13.
Status change: Not Yet Recruiting → Recruiting 2024-11-14
Trial Details
NCT Number NCT06663358
Lead Sponsor Chiesi Farmaceutici S.p.A.
Conditions Fabry Disease
Enrollment 100 participants
Start Date 2024-11-06
Primary Completion 2029-11 (estimated)
Study Completion 2029-11 (estimated)
Updated on ClinicalTrials.gov 2025-11-14